Olanzapine

Generic Name: Olanzapine

Brand Names: Lybalvi, Olazax, Symbyax, Zalasta, Zypadhera, Zyprexa, Olanzapine Glenmark Europe, Olanzapine Apotex, Olanzapine Teva, Olazax Disperzi, Olanzapine Mylan, Zyprexa Velotab, Olanzapine Glenmark

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₂₀N_₄S

CAS Number: 132539-06-1

Unique Ingredient Identifier: N7U69T4SZR

Background: Olanzapine is a thienobenzodiazepine classified as an atypical or second-generation antipsychotic agent. The second-generation antipsychotics were introduced in the 90s and quickly gained traction due to their impressive efficacy, reduced risk for extrapyramidal side effects and reduced susceptibility to drug-drug interactions. Olanzapine very closely resemb...

Indication: Olanzapine was initially used orally and intramuscularly for the chronic treatment of schizophrenia in patients over 13 years old and other psychiatric disorders such as bipolar I disorder including mixed or manic episodes.
...

Associated Conditions: Acute Agitation, Bipolar 1 Disorder, Bipolar Disorder With Manic or Mixed Episodes, Delirium, Delusional Parasitosis, Depressive Episodes, Gilles de la Tourette's Syndrome, Major depressive disorder, recurrent episode, Mixed manic depressive episode, Post Traumatic Stress Disorder (PTSD), Psychosis, Schizophrenia, Acute Manic episode

Associated Therapies: -

Clinical Trials

A Combination of Two Currently Approved Drugs to Enhance the Treatment of Schizophrenia

Phase 1

Completed

Conditions: Schizophrenia

First Posted Date: 2004-08-18

Last Posted Date: 2006-07-20

Lead Sponsor: Eli Lilly and Company

Registration Number: NCT00089869

Locations: 🇺🇸
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician., Chula Vista, California, United States
🇺🇸
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician., Irving, Texas, United States
🇺🇸
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician.", San Antonio, Texas, United States

Efficacy and Safety of Olanzapine in Patients With Borderline Personality Disorder

Phase 3

Completed

Conditions: Borderline Personality Disorder

First Posted Date: 2004-07-21

Last Posted Date: 2006-07-24

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 450

Registration Number: NCT00088036

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician, New Haven, Connecticut, United States
🇹🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Istanbul, Capa, Turkey

Study of Olanzapine vs. Aripiprazole in the Treatment of Schizophrenia

Phase 4

Completed

Conditions: Schizophrenia

First Posted Date: 2004-07-21

Last Posted Date: 2007-07-18

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 560

Registration Number: NCT00088049

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Salt Lake City, Utah, United States

Depakote ER Plus an Atypical Antipsychotic Vs. an Atypical Antipsychotic Alone in the Treatment of Schizophrenia

Phase 2

Completed

Conditions: Schizophrenia

First Posted Date: 2003-11-18

Last Posted Date: 2006-08-04

Lead Sponsor: Abbott

Target Recruit Count: 400

Registration Number: NCT00073164

Depakote Monotherapy, Olanzapine Monotherapy, and Combination Therapy of Depakote Plus Olanzapine in Stable Subjects During the Maintenance Phase of Bipolar Illness

Phase 4

Terminated

Conditions: Bipolar Disorder

First Posted Date: 2003-10-20

Last Posted Date: 2006-08-04

Lead Sponsor: Abbott

Target Recruit Count: 180

Registration Number: NCT00071253

Locations: 🇺🇸
Rush Presbyterian - St. Luke's, Chicago, Illinois, United States
🇺🇸
UTMB Dept. of Psychiatry, Galveston, Texas, United States
🇺🇸
University of Mississippi Medical Center, Jackson, Mississippi, United States

and more 12 locations

Atypical Neuroleptic Drugs in People With Mental Retardation/Developmental Delay

Phase 3

Completed

Conditions: Mental Retardation
Developmental Delay Disorder

First Posted Date: 2003-07-22

Last Posted Date: 2005-06-24

Lead Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Target Recruit Count: 50

Registration Number: NCT00065273

Locations: 🇺🇸
University of Kansas, Lawrence, Kansas, United States

Study of Pharmacotherapy of Psychotic Depression

Phase 3

Completed

Conditions: Major Depressive Disorder With Psychotic Features

Interventions: Drug: Olanzapine
Other: placebo
Drug: Sertraline

First Posted Date: 2003-03-17

Last Posted Date: 2013-08-02

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 259

Registration Number: NCT00056472

Locations: 🇺🇸
University of Massachusetts Medical School, Worcester, Massachusetts, United States
🇨🇦
University of Toronto, Toronto, Ontario, Canada
🇺🇸
Cornell University, New York, New York, United States

and more 1 locations

Olanzapine Versus Placebo in the Treatment of Adolescents With Schizophrenia

Phase 3

Completed

Conditions: Schizophrenia

First Posted Date: 2003-01-09

Last Posted Date: 2007-06-12

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 107

Registration Number: NCT00051298

Locations: 🇷🇺
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hrs, EST), or speak with your personal physician., Moscow, Russian Federation
🇺🇸
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician, Cerritos, California, United States

Olanzapine Versus Placebo in the Treatment of Mania in Adolescents With Bipolar I Disorder

Phase 4

Completed

Conditions: Bipolar Disorder

First Posted Date: 2002-11-27

Last Posted Date: 2007-06-12

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 130

Registration Number: NCT00050206

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hrs, EST), or speak with your personal physician., Indianapolis, Indiana, United States

Treating Drug-Resistant Childhood Schizophrenia

Phase 4

Completed

Conditions: Schizophrenia

Interventions: Drug: Clozapine
Drug: Olanzapine

First Posted Date: 2002-11-13

Last Posted Date: 2013-07-02

Lead Sponsor: Northwell Health

Target Recruit Count: 41

Registration Number: NCT00048828

Locations: 🇺🇸
Sagamore Children's Psychiatric Center, Dix Hills, New York, United States
🇺🇸
Bronx Children's Psychiatric Center, Bronx, New York, United States
🇺🇸
Long Island Jewish Medical Center, Glen Oaks, New York, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy